<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161394</url>
  </required_header>
  <id_info>
    <org_study_id>1851</org_study_id>
    <nct_id>NCT01161394</nct_id>
  </id_info>
  <brief_title>Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study</brief_title>
  <official_title>Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pioglitazone decreases oxidative load, inflammatory end points and improves vascular&#xD;
      reactivity in obese patients in a dose dependent manner and that this effect is independent&#xD;
      of its glucose lowering effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open labeled study. A total of 24 obese patients will be recruited&#xD;
      to participate in this study. The study will have three groups of 8 patients each. Subjects&#xD;
      will be enrolled into each group by alternate recruitment. Subjects in group one will receive&#xD;
      15mg of pioglitazone; subjects in group two will receive 30 mg of pioglitazone; subjects in&#xD;
      group three will receive placebo. All subjects will receive Pioglitazone or placebo for 6&#xD;
      weeks, followed by a 6-week observation period off Pioglitazone/placebo.&#xD;
&#xD;
      At baseline, and at week 1, week 2, week 4, week 6 and month 3 all patients will have blood&#xD;
      drawn for TBARS, ortho and meta-tyrosine, 9-HODE and 13-HODE, NF, Ikb, TNF-a, ICAM-1, VCAM-1,&#xD;
      PAI-1, AP-1, EGR-1, MMP-2, MMP-9, TIMP, CRP-1, E-Selectin, P-Selectin, Asymmetric&#xD;
      dimethylarginine (ADMA), PAPP-A, SAA, MCP-1, IL-6, ROS generation, insulin levels, and CRP.&#xD;
&#xD;
      Post-ischemic dilation of the brachial artery will be used as an index of&#xD;
      endothelium-mediated vasodilation. All subjects will have an oral glucose tolerance test&#xD;
      (GTT) with 75gm of glucose at Day 0 and at Day 42. Vascular reactivity will be assessed at 0,&#xD;
      6, and at 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">October 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change in NFkb at baseline and after 1, 2, 4, 6, and 12 weeks of pioglitazone therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>12 weeks</time_frame>
    <description>TBARS (Thiobarbituric acid reactive substances), ortho and meta-tyrosine, 9-HODE and 13-HODE (hydroxyoctadecadieonic acid derivatives), Cellular/nuclear fractions and DNA binding activity of Nuclear Factor kb, Ikb (inhibitory kappa B), TNF-a(Tumor necrosis factor a), ICAM-1 (Intracellular adhesion molecule 1), VCAM-1(Vascular adhesion molecule 1), PAI-1 (Plasminogen Activator Inhibitor -1) and CRP (C-Reactive protein) and %change in vascular reactivity.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Pioglitazone 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 patient will receive this drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pioglitazone 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 patients will get this drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 patient will get this drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 15mg</intervention_name>
    <arm_group_label>Pioglitazone 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone 30mg</intervention_name>
    <arm_group_label>pioglitazone 30mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Obese (BMI&gt;=30)&#xD;
&#xD;
               -  Age: 20 to 65 years of age inclusive&#xD;
&#xD;
               -  Without established clinical coronary artery disease (documented history or&#xD;
                  myocardial infarction, typical angina and an exercise ECG positive for ischemia&#xD;
                  or angiographic evidence of CAD)&#xD;
&#xD;
               -  Good health as evidence by History and Physical exam&#xD;
&#xD;
               -  Female subjects must be:&#xD;
&#xD;
        Postmenopausal for at least one year or Surgically incapable of childbearing (i.e. have had&#xD;
        a hysterectomy or tubal ligation) or, if capable of childbearing a subject, must be&#xD;
        practicing an acceptable method of contraception.&#xD;
&#xD;
        • Subject will be available for duration of the study and willing to comply with all study&#xD;
        requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Diabetes Mellitus&#xD;
&#xD;
               -  Allergy or sensitivity to Pioglitazone&#xD;
&#xD;
               -  Current use of Insulin therapy.&#xD;
&#xD;
               -  Coronary event or procedure (myocardial infarction, unstable angina, coronary&#xD;
                  artery bypass, surgery or coronary angioplasty) in the previous four weeks&#xD;
&#xD;
               -  Hepatic disease (transaminase &gt; 3 times normal)&#xD;
&#xD;
               -  Renal impairment (Creatinine clearance &lt; 50 mL/min)&#xD;
&#xD;
               -  History of drug or alcohol abuse&#xD;
&#xD;
               -  COPD&#xD;
&#xD;
               -  Participation in any other concurrent clinical trial&#xD;
&#xD;
               -  Any other life-threatening, non-cardiac disease&#xD;
&#xD;
               -  Use of an investigational agent or therapeutic regimen within 30 days of study&#xD;
&#xD;
               -  Pregnancy or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaleida Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Millard Fillmore gates Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <name_title>Paresh Dandona</name_title>
    <organization>University at buffalo Kaleida Health</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

